中文簡介

腫瘤學(xué)研究致力于出版高質(zhì)量、創(chuàng)新性的研究，重點是臨床前、轉(zhuǎn)化和臨床癌癥治療的整個范圍。感興趣的具體領(lǐng)域包括開發(fā)新型小分子和靶向治療的臨床前和轉(zhuǎn)化研究；藥物敏感性機制；細胞藥物抵抗機制；反應(yīng)和/或抵抗的生物標(biāo)志物；與癌癥治療相關(guān)的新型實驗?zāi)Ｐ拖到y(tǒng)和技術(shù)；藥物遺傳學(xué)和藥物基因組學(xué)；個性化醫(yī)學(xué)；免疫治療和臨床免疫學(xué)；基因治療；放射生物學(xué)和放射治療的新方法?；蚺c化療結(jié)合使用。作為臨床前癌癥治療焦點的一部分，該雜志還將重點放在藥物設(shè)計、化學(xué)生物學(xué)和藥物篩選方面的臨床前研究。雖然該雜志的主要關(guān)注點是小分子和蛋白質(zhì)藥物，但也可以考慮其他分子實體。此外，歡迎提交研究草藥/植物藥在臨床前和臨床癌癥治療中的潛在作用的報告；但是，重要的是要證明這些藥物具有高質(zhì)量，并確認批次間的一致性。除了最初的同行評議的文章外，該雜志還歡迎及時評論和/或評論關(guān)注臨床前、轉(zhuǎn)化和/或臨床癌癥治療的主題。

投稿網(wǎng)址：orjournal@gmail.com

英文簡介

Oncology Research is committed to publishing high-quality, innovative research that is focused on the entire range of preclinical, translational, and clinical cancer therapeutics.Specific areas of interest include preclinical and translational research in development of novel small molecules and targeted therapies; mechanisms of drug sensitivity; mechanisms of cellular drug resistance; biomarkers of response and/or resistance; novel experimental model systems and technologies relating to cancer therapeutics;pharmacogenetics and pharmacogenomics; personalized medicine; immunotherapy and clinical immunology; gene therapy; and radiobiology and novel approaches to radiation therapy either alone or in combination with chemotherapy. As part of the preclinical cancer therapeutics focus, the journal also prioritizes preclinical studies that are focused on drug design, chemical biology, and drug screening. While the journal’s primary focus is on small molecules and protein drugs, other molecular entities may be considered. In addition, submissions that investigate the potential role of herbal/botanical medicines in preclinical and clinical cancer therapy are welcomed; however, it will be important to document that these medicines are of high quality, with confirmation of batch to batch consistency. In addition to original peer-reviewed articles, the journal also welcomes timely reviews and/or commentaries on topics that focus on preclinical, translational, and/or clinical cancer therapeutics.